Meningococcal vaccine

Meningococcal vaccine refers to any <a href="/facts/Vaccine/QcXzLug2">vaccine</a> used to prevent infection by <a href="/facts/Neisseria_meningitidis/u4SqwHuc">Neisseria meningitidis</a>. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in <a href="/facts/Meningitis/4m4STzJB">meningitis</a> and <a href="/facts/Sepsis/n52bkffJ">sepsis</a> among populations where they are widely used. They are given either by <a href="/facts/Intramuscular/PPNwW2wB">injection into a muscle</a> or <a href="/facts/Subcutaneous_injection/L4srK61u">just under the skin</a>.
The <a href="/facts/World_Health_Organization/YNN3bgug">World Health Organization</a> recommends that countries with a moderate or high rate of disease or with frequent outbreaks should <a href="/facts/Vaccination_schedule/vfHSxP7j">routinely vaccinate</a>. In countries with a low risk of disease, they recommend that high-risk groups should be immunized. In the <a href="/facts/African_meningitis_belt/E932YGqu">African meningitis belt</a> efforts to immunize all people between the ages of one and thirty with the meningococcal A <a href="/facts/Conjugate_vaccine/DwqFnI4L">conjugate vaccine</a> are ongoing. In <a href="/facts/Canada/cWWFM8oc">Canada</a> and the <a href="/facts/United_States/P0sCdLe5">United States</a> the vaccines are effective against four types of meningococcus (A, C, W, and Y) are recommended routinely for teenagers and others who are at high risk. Saudi Arabia requires vaccination with the quadrivalent vaccine for international travellers to <a href="/facts/Mecca/udqyuk0k">Mecca</a> for <a href="/facts/Hajj/eDC5AalN">Hajj</a>.
Meningococcal vaccines are generally safe. Some people develop pain and redness at the injection site. Use in pregnancy appears to be safe. <a href="/facts/Anaphylaxis/F9IDQxeL">Severe allergic reactions</a> occur in less than one in a million doses.
The first meningococcal vaccine became available in the 1970s. It is on the <a href="/facts/WHO_Model_List_of_Essential_Medicines/6kmu81Xm">World Health Organization's List of Essential Medicines</a>.
Inspired by the response to the 1997 outbreak in Nigeria, the WHO, <a href="/facts/M%C3%A9decins_Sans_Fronti%C3%A8res/aWHStTIt">Médecins Sans Frontières</a>, and other groups created the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control, which manages global response strategy. ICGs have since been created for other epidemic diseases.

Meningococcal vaccine open-in-new

Meningococcal vaccine